Summary
Catalepsy was observed in the rat following intrastriatal injections of the dopamine antagonists sulpiride or fluphenazine and after subcutaneous administration of fluphenazine. The neuroleptic-induced catalepsy was reversed by the classical anti-parkinsonian agent L-DOPA and by agents that function through dopamine systems such as d- and methamphetamine and the direct D2 receptor agonist quinpirole. The D1 agonist SKF 38393, and the D1/D2 agonist apomorphine, were ineffective in this model. These results support limited use of the rat catalepsy model for the screening of potential anti-parkinsonian compounds and indicate that this procedure can provide valuable information concerning striatal dopamine function.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Andrews CD, Woodruff GN (1978) Effect of the (+) and (−) enantiomers of sulpiride on ADTN-induced hyperactivity in the rat. Br J Pharmacol 64: 434
Antleman SM, Kocan D, Edwards DJ, Knopf S, Perel JM, Stiller R (1986) Behavioural effects of a single neuroleptic treatment grow with the passage of time. Brain Res 385: 58–67
Barker R, Duncan J, Lees A (1989) Subcutaneous apomophine as a diagnostic test for dopaminergic responsivness in Parkinsonian syndromes. Lancet i: 675
Barone P, Bankiewicz KS, Corsini GU, Kopin IJ, Chase TN (1987) Dopaminergic mechanisms in hemiparkinsonian monkeys. Neurology 37: 1592–1595
Braun A, Fabbrini G, Mouradian MM, Serrati C, Barone P, Chase TN (1986) Selective D-1 dopamine receptor agonist treatment of Parkinson's disease. J Neural Transm 68: 41–50.
Christensen AV, Arnt J, Hyttel J, Larsen JJ, Svendsen O (1984) Pharmacological effects of a specific dopamine D-1 antagonist SCH 23390 in comparison with neuroleptics. Life Sci 34: 1529–1540
Clark D, White FJ (1987) Review: D 1 dopamine receptor — the search for a function: a critical evaluation of the D 1/D 2 dopamine receptor classification and its functional implications. Synapse 1: 347–388
Close SP, Marriott AS, Pay S (1985) Failure of SKF 38393A to relieve parkinsonian symptoms induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the marmoset. Br J Pharmacol 85: 320–322
Costall B, Olley JE (1971) Cholinergic- and neuroleptic-induced catalepsy: modification by lesions in the caudate-putamen. Neuropharmacology 10: 297–306
Creese I, Sibley DR, Hamblin MW, Leff SE (1983) The classification of dopamine receptors: relationship to radioligand binding. Ann Rev Neurosci 6: 43–71
Dunnett SB, Iversen SD (1982) Spontaneous and drug-induced rotation following localized 6-hydroxydopamine and kainic acid-induced lesions of the neostriatum. Neuropharmacology 21: 899–908
Ellenbroek B, Cools AR (1988) The paw test: an animal model for neuroleptic drugs which fulfills the criteria for pharmacological isomorphism. Life Sci 42: 1205–1213
Elliott PJ (1986) A reliable, rapid and inexpensive method for producing and implanting chronic cannulae into brains of small animals. Pharmacol Biochem Behav 24: 1809–1811
Fog R, Randrup A, Pakkenberg H (1970) Lesions in corpus striatum and cortex of rat brains and the effect on pharmacologically induced stereotyped aggressive and cataleptic behaviour. Psychopharmacology 10: 246–256
Hornykiewicz O (1973) Dopamine in the basal ganglia. Br Med Bull 29: 172–178
Hornykiewicz O (1979) Brain dopamine in Parkinson's disease and other neurological disturbances. In: Horn AS, Korf J, Westerink BHC (eds) The neurobiology of dopamine. Academic Press, London, pp 633–654
Hondo F, Satoh V, Shimomura K, Satoh H, Noguchi H, Uchida S, Kato R (1977) Dopamine receptor Glocking activity of sulpiride in the central nervous system. Jpn Pharmacol 27: 397–411
Hytell J, Arnt J (1986) Characterization of dopamine D1 and D2 receptors. In: Breese GR (ed) Neurobiology of central D 1 dopamine receptors. Plenum Press, New York, pp 15–28
Klemm WR (1985) Neuroleptic-induced catalepsy: a D-2 blockade phenomenon? Pharmacol Biochem Behav 23: 911–915
Klemm WR, Block H (1987) D-1 and D-2 receptor blockade have additive cataleptic effects in mice, but receptor effects may interact in opposite ways. Pharmacol Biochem Behav 29: 223–229
Liberman AN, Goldstein M (1982) Treatment of advanced Parkinson's disease with dopamine agonists. In: Marsden CD, Fahn S (eds) Movement disorders. Butterworth, London, p 146
Meller E, Kuga S, Friedhoff AJ, Goldstein M (1985) Selective D-2 dopamine receptor agonists prevent catalepsy induced by SCH 23390, a selective D-1 antagonist. Life Sci 36: 1857–1864
Miller RJ, Kelly PH, Neumeyer JL (1976) Action of aporphine alkaloids on dopaminergic mechanisms in rat brain. Eur J Pharmacol 35: 77–83
Morelli M, Di Chiara G (1985) Catalepsy induced by SCH23390 in rats. Eur J Pharmacol 117: 179–185
Niemegeers CJE, Janssen PAJ (1979) A systematic study of the pharmacological activities of dopamine antagonists. Life Sci 24: 2201–2216
Nomoto M, Jenner P, Marsden CD (1985) The dopamine D-2 agonist LY141865 but not the D-1 agonist SKF 38393 reverses parkinsonism induced by 1-methyl-4-pheny-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset. Neurosci Lett 57: 37–41
O'Boyle KM, Pugh M, Waddington JL (1984) Stereotypy induced by the D-1 dopamine agonist RU24213 is blocked by the D-2 antagonist RO22-2586 and the D-1 antagonist SCH 23390. Br J Pharmacol 82: 242
O'Boyle KM, Waddington JL (1987) New substituted 1-phenyl-3-benzazepine analogues of SKF 38393 and N-methyl-thienopyridine analogues of dihydroxynomifensine with selective affinity for the D-1 dopamine receptor in human post-mortem brain. Neuropharmacology 26: 1807–1810
Poewe W, Kleedorfer B, Wagner M, Berke T, Gasser T, Ooentel W (1989) Side effects of subcutaneous apomorphine in Parkinson's disease. Lancet i: 1084–1085
Sanberg PR (1980) Haloperidol-induced catalepsy is mediated by postsynaptic dopamine receptors. Nature 284: 472–473
Seeman P, Bzowej NH, Guan HC, Bergeron C, Reynolds GP, Bird ED, Riederer P, Jellinger K, Tourtellotte WW (1987) Human brain D-1 and D-2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases. Neuropsychopharmacology 1: 5–15
Stanley ME, Glick SD (1976) Interaction of drug effects with testing procedures in the measurement of catalepsy. Neuropharmacology 15: 393–394
Undie AS, Friedman E (1988) Difference in the cataleptogenic actions of SCH 23390 and selected classical neuroleptics. Psychopharmacology 96: 311–316
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Elliott, P.J., Close, S.P., Walsh, D.M. et al. Neuroleptic-induced catalepsy as a model of Parkinson's disease I. Effect of dopaminergic agents. J Neural Transm Gen Sect 2, 79–89 (1990). https://doi.org/10.1007/BF02260896
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02260896